Abstract: . . .  15. Couban S, Goodyear M, Burnell M, et al. A randomized double-blind placebo-controlled study of low-dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. [abstract] Blood 2002; 100(suppl):703a. 16. Lee AYY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25:137-145. 17. Levine M, Kirsh J, Gent M, et al. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886-889. 18. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the Natioanl Surgical Adjuvant Breast and Bowl Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388. 19. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083. 20. Prandoni P, Lensing AWA, Piccioli A, Bernardi E. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis . Blood 2002; 100:3484-3488. 21. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med 2003;349:146-153 Clinical Guide: Cancer & Thrombosis  . . .
--3000,1,1500,1729,15867